Anjali Hari, MD, discusses survival and safety outcomes with hyperthermic intraperitoneal chemotherapy in frail and non-frail patients with ovarian cancer.
In an interview with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Anjali Y. Hari, MD, an obstetrician-gynecologist at the University of California (UC), Irvine, School of Medicine, spoke about efficacy and safety findings with hyperthermic intraperitoneal chemotherapy (HIPEC) in frail and non-frail patients with ovarian cancer.
In particular, Hari stated that a nonsignificant difference in progression-free survival (PFS) was observed between the frail and non-frail groups. Additionally, no notable difference in safety was observed.
The survival outcomes were very similar. PFS was about 12 months for frail patients vs 14 months for non-frail patients, but this was not significant. Then postoperatively, hospital stays, ICU stays, sepsis, and anastomotic leak rates were all very similar between frail and non-frail patients. Again, there were no big safety issues, which we found was a good thing. Our patients did very similarly postoperatively in terms of their hospital stays, and complications.
Hari A, Furey K, Jou J, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) outcomes across 3 academic institutions among frail and non-frail patients. Presented at: Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer. March 18-21, 2022. Phoenix, AZ.